DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Sibling Oocyte Study of Medium for In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) With no Human Serum Albumine

Information source: Sykehuset Telemark
ClinicalTrials.gov processed this data on November 27, 2014
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: In Vitro Fertilization; Infertility

Intervention: Medium with no human serum albumine added (Other); Conventional medium (Other)

Phase: Phase 2

Status: Recruiting

Sponsored by: Sykehuset Telemark

Official(s) and/or principal investigator(s):
Jarl Kahn, Dr. Med, Study Director, Affiliation: Fertilitetsklinikken Sør

Overall contact:
Jarl Kahn, Dr. med., Phone: +47 35005820, Email: Jarl.Arne.Kahn@sthf.no

Summary

The purpose of this study is to determine if a new medium with no human serum albumine added is as good as the media conventionally used for IVF/ICSI.

Clinical Details

Official title: Sibling Oocyte Study of Medium for IVF/ICSI With no Human Serum Albumine

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Fertilization

Cleavage

Embryo score

Embryos used

Detailed description: Cells attained in IVF/ICSI procedures are kept in a medium that nurture the cells. Until now all such media have contained human serum albumine. The purpose of this study is to determine if a new medium with no human serum albumine added is as good as the media conventionally used for IVF/ICSI.

Eligibility

Minimum age: 18 Years. Maximum age: 38 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Couples seeking IVF/ICSI.

- Female under 38 years of age.

- No more than two previous IVF/ICSI treatments without pregnancy.

- Regular menstruation periods.

- No endocrine disease that requires treatment in the female.

- BMI below 30 in the female.

- At least 8 mature follicles upon monitoring or 6 MII oocytes upon ICSI.

- Written informed consent.

Exclusion Criteria:

- Low responders to FSH.

- Females in danger of developing OHSS.

- Sperm sample below ICSI-quality.

Locations and Contacts

Jarl Kahn, Dr. med., Phone: +47 35005820, Email: Jarl.Arne.Kahn@sthf.no

Fertilitetsklinikken Sør, Porsgrunn, Telemark 3901, Norway; Recruiting
Jarl Kahn, Dr. Med, Phone: +47 35005820, Email: Jarl.Arne.Kahn@sthf.no
Additional Information

Starting date: September 2007
Last updated: July 20, 2011

Page last updated: November 27, 2014

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014